
Invacare Corporation IVC
Quarterly report 2023-Q1
added 05-15-2023
Invacare Corporation Accounts Receivables 2011-2026 | IVC
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 88 M | 117 M | 109 M | 117 M | 120 M | 126 M | 116 M | 134 M | 160 M | 189 M | 199 M | 248 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 248 M | 88 M | 143 M |
Quarterly Accounts Receivables Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.7 M | 88 M | 80.1 M | 90.9 M | 106 M | 117 M | 116 M | 121 M | 99.8 M | 109 M | 109 M | 93.9 M | 109 M | 117 M | 117 M | 117 M | 117 M | 120 M | 120 M | 120 M | 120 M | 126 M | 126 M | 126 M | 126 M | 116 M | 116 M | 116 M | 116 M | 129 M | 129 M | 134 M | 134 M | 154 M | 154 M | 154 M | 160 M | 189 M | 189 M | 189 M | 189 M | 199 M | 199 M | 199 M | 199 M | 210 M | 248 M | 248 M | 248 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 248 M | 80.1 M | 141 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
566 M | $ 36.74 | - | $ 5.47 K | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 9.38 | - | $ 266 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.59 | - | $ 36.7 M | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 12.07 | - | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 9.7 | - | $ 347 M | ||
|
EDAP TMS S.A.
EDAP
|
17.9 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Edwards Lifesciences Corporation
EW
|
660 M | $ 81.19 | - | $ 47.5 B | ||
|
Globus Medical
GMED
|
679 M | $ 88.6 | - | $ 12 B | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 1.9 | - | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 54.14 | - | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.0 | - | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 85.63 | - | $ 2.97 B | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.94 | - | $ 374 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Medtronic PLC
MDT
|
6.52 B | $ 86.28 | - | $ 111 B | ||
|
Align Technology
ALGN
|
996 M | $ 171.87 | - | $ 12.9 B | ||
|
Myomo
MYO
|
4.1 M | $ 0.7 | - | $ 29.3 M | ||
|
AxoGen
AXGN
|
26.2 M | $ 32.64 | - | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Orthofix Medical
OFIX
|
136 M | $ 11.77 | - | $ 466 M | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
Penumbra
PEN
|
190 M | $ 329.87 | - | $ 12.8 B | ||
|
Insulet Corporation
PODD
|
161 M | $ 203.5 | - | $ 14.3 B | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.53 | 0.4 % | $ 7.02 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 4.13 | -0.24 % | $ 874 M | ||
|
Stryker Corporation
SYK
|
4.04 B | $ 332.3 | - | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
43.9 M | $ 24.57 | - | $ 562 M | ||
|
TELA Bio
TELA
|
10.3 M | $ 0.63 | 5.47 % | $ 29.6 M | ||
|
TransMedics Group
TMDX
|
84.3 M | $ 104.8 | - | $ 3.56 B | ||
|
Tandem Diabetes Care
TNDM
|
165 M | $ 19.17 | - | $ 1.3 B | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M |